Correlation of Tissue Biopsy and Fine Needle Aspiration Cytology with Positron Emission Tomography Results
Open Access
- 6 April 2011
- journal article
- Published by Hindawi Limited in Pathology Research International
- Vol. 2011, 1-7
- https://doi.org/10.4061/2011/323051
Abstract
F-18-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scans are positive in any condition which increases metabolism in a mass or tissue and are therefore not specific for neoplastic conditions. The use of an SUV cutoff value of 2.5 may not always help discriminate between benign and malignant cases. For a practicing cytopathologist doing adequacy checks during an image-guided procedure, it may be of value to be aware that elevated SUV values are not always indicative of a malignant process, and vice versa.Keywords
This publication has 30 references indexed in Scilit:
- Positron Emission Tomography for Benign and Malignant DiseaseSurgical Clinics of North America, 2011
- Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in LymphomaThe Oncologist, 2009
- 18F-Fluorodeoxiglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal CancerAnnals of Surgery, 2009
- Fine Needle Aspiration Outcomes of Masses Detected by Positron Emission TomographyActa Cytologica, 2007
- The Maximum Standardized Uptake Values on Integrated FDG-PET/CT Is Useful in Differentiating Benign From Malignant Pulmonary NodulesThe Annals of Thoracic Surgery, 2006
- Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2006
- NICE issues guidance for diagnosis and treatment of lung cancerBMJ, 2005
- 18‐Fluoro‐2‐deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imagingCancer, 2003
- Imaging in lung cancer: positron emission tomography scanEuropean Respiratory Journal, 2002
- PET in oncology: Will it replace the other modalities?Seminars in Nuclear Medicine, 1997